Eurofins Clinical Trial Solutions’ Post

We are please to announce that our latest paper on the development of oncolytic coxsackievirus B3 (CVB3) against pancreatic cancer has now been published in the International Journal of Molecular Sciences. Oncolytic viruses are a therapeutic tool that destroys cancer cell, while leaving healthy cells unaffected. In the present study, the PD-H variant of was shown to destroy pancreatic cancer cells and to inhibit tumor growth in vivo (without completely stopping tumor progression). This treatment strategy may develop into a new treatment option for pancreatic cancer, which is currently particularly difficult to treat. Please read the full study here: https://lnkd.in/eK2e3q3E

Are you heading to the American Association for Cancer Research Conference (AACR) in San Diego? On Monday April 8, at 1:30pm, join Dewpoint's Head of Biology Ann Boija, Ph.D., who will be presenting the latest data from our colorectal cancer program (Poster section 53 - Poster Board 15 – Abstract LB199). These new data demonstrate how we were able to leverage condensate biology to discover small molecule condensate-modulators (c-mods) that reverse the hyperactive function of beta-catenin by entrapping it into depot condensates across models of genetically diverse colorectal cancers and several Wnt-associated cancers. These results highlight the promise of condensate biology in drugging previously intractable oncology targets and for developing novel treatments for patients suffering from diseases with high unmet need. Read about Ann’s ambitions for biomolecular condensates in oncology: https://lnkd.in/e5vuzDJs #AACR24

Exciting research published in Nature Metabolism led by Professor Leng Han (Indiana University School of Medicine) sheds light on the impact of tumor hypoxia on cancer treatment resistance. Evidently, tumor hypoxia plays a dominant role in treatment resistance and relapse of cancer. The study reveals that patients with hypoxic tumors – irrespective of tumor type – expects a 3-year shorter survival on average compared to patients with less hypoxic tumors.* This underscores the need for a broadly applicable and effective hypoxia-targeted therapy. Kripthonite Therapeutics’ innovative therapy holds promise for closing this survival gap by eliminating hypoxic cancer cells in solid tumors through targeting specific metabolic changes in hypoxic cancer cells. Stay tuned for more updates on the future of hypoxia-targeted therapy in oncology! *https://lnkd.in/dvfT_5Zy | Erik Vinther | Per Hjerrild | Kristian Mark Jacobsen | Peter Horn Møller | Thomas Poulsen | Charlotte Dyring, PhD | Benny Buchardt Andersen | #CancerResearch #HypoxiaTreatment #PersonalizedMedicine #TumorHypoxia

μCaler EMS Panel Covers CpG sites of multiple genes for 9 major cancer types in a single detection!!! μCaler EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It encom passes nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma ca ncer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinog enesis and tumor suppression, with over 2,000 CpG sites. https://lnkd.in/g365m-MR #μCaler #Methylation #Nanodigmbio

🌟 Exciting Announcement! 🌟 🔬 Delighted to share that Prof. Valentina De Falco has established a Special Issue in oncology research titled: "Kinase and Phosphatase Signaling Modulation to Overcome Resistance to Conventional Anticancer Therapies" . 🔍This special issue seeks to bring together a series of original research articles and updated reviews spanning all aspects of precision medicine through the identification of novel targets in tumor oncology. Work that helps decipher molecular changes and identify biomarkers and predictors of prognosis, as well as advances in therapeutic options with the identification of resistance mechanisms, are central topics, as are contributions on other significant topics that further improve our understanding of the molecular immunotherapy and all targeted anti-tumor therapies. 🚀 Let's accelerate progress together! Check out the Special Issue now and contribute to shaping the future of cancer therapy. https://lnkd.in/d3-5h5iA #OncologyResearch #CancerTherapies #Innovation #SpecialIssue #ResearchCommunity

EACR Signaling Circuits in Cancer! Taking place online from 13 - 14 February 2024, this conference will focus on basic mechanisms controlling cancer cell signaling circuits at the epigenome, transcriptome, proteome, and phosphoproteome levels. The talks will also focus on therapeutic targeting of cancer cell signaling circuits by conventional and emerging pharmacological strategies, as well as the mechanistic aspects of post- translational and transcriptional regulation of cancer cell signaling, as well as large OMICS-based global understanding of cancer cell signaling circuits.

Today, we announced a National Cancer Institute funded Ph1b/2 clinical collaboration with UT Health San Antonio and Sobi - Swedish Orphan Biovitrum AB (publ)® based on UT Health San Antonio’s ground breaking research published in Cell Reports in September 2023 and Cancer Research in April 2020. We will collaborate to study BerGenBio’s selective #AXL inhibitor, #bemcentinib, in combination with Sobi - Swedish Orphan Biovitrum AB (publ)’s JAK2 inhibitor, pacritinib, in patients with advanced lung adenocarcinoma. The Ph1b/2 study will be led by Dr. Josephine Taverna, MD, at the Mays Cancer Center and Assistant Professor in the Division of Hematology and Oncology at UT Health San Antonio and is based on Dr. Taverna and colleagues’ research demonstrating that #AXL and JAK-STAT3 work together to transmit signals that promote tumor growth and metastasis in advanced #lungcancer. #bemcentinib #AXL #lungcancer

🧬 Advances in Cancer Metabolism: Explore Groundbreaking Research 🧬 Stay ahead in cancer research with the latest findings from the Molecular Oncology Focus Issue. This special edition highlights key discoveries in: 🔬 Metabolic Reprogramming: Learn how this process is key to overcoming drug resistance in advanced cancers. 🧠 Cancer Cachexia: Discover the latest biomarkers and how they influence cancer treatment strategies. 🧫 Bladder & Endometrial Cancer: Delve into research that sheds light on metabolic pathways in these challenging cancers. ⚛️ Ribosome Biogenesis: Explore its critical role in tumor growth and cancer progression. These studies offer insights for oncologists, molecular biologists, immunologists, and cancer researchers. 🌐 📝 Read the full issue and enhance your research with the latest in cancer metabolism: https://lnkd.in/dR5xpfhi #CancerResearch #Oncology #CancerMetabolism #RibosomeBiogenesis #BladderCancer #EndometrialCancer #CancerCachexia

🌐 Advancing Cancer Diagnostics with MP-SPR! 🌐 Discover how BioNavis Oy is setting new standards in cancer diagnostics. Their latest research explores the potent capabilities of MP-SPR in the early detection of ovarian cancer through non-invasive methods. 🔎 Key Outcomes: Real-Time Analysis: MP-SPR offers a label-free, highly sensitive approach to measure the interactions of extracellular vesicles and specific proteins, providing immediate insights into cellular communication and disease markers. Precision in Cancer Research: The study highlighted MP-SPR's effectiveness in identifying specific tumor markers (α3β1 integrin), offering a promising avenue for early cancer detection and potential therapeutic interventions. Leverage MP-SPR for cutting-edge diagnostics and enhance your research capabilities in the fight against cancer. #CancerResearch #Diagnostics #MPSPR #LifeSciences #Innovation

Cancer Tumorigenesis and Cancer Biomaker Today we are reaching new heights in Cancer Tumorigenesis and Cancer Biomarkers with the help of our authors and researchers who contribute with their valuable research. And here is some information about Cancer Tumorigenesis and Cancer Biomaker. The complex process of cancer development, involves genetic mutations, epigenetic changes, and environmental factors, leading to uncontrolled cell growth and tumor formation. Cancer Biomarkers:- Molecular signatures or indicators of cancer presence, progression, or response to treatment, enabling early detection, diagnosis, and personalized medicine. Understanding tumorigenesis and biomarkers is crucial for cancer prevention, treatment, and research. Submit your work related to the Journal of Cancer Therapy and Research here: https://lnkd.in/gdU5iHy Access our Journal here: https://lnkd.in/dHQkEAMe For any queries contact us on Whatsapp@ +1(438) 699-5365 #CancerTumorigenesis #CancerBiomarkers #CancerResearch #Oncology #PrecisionMedicine #CancerDiagnosis #CancerTreatment #MolecularOncology #CancerGenetics #CancerEpigenetics #BiomarkerDiscovery #genesispuborg